FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Rheumatoid Arthritis topics
Rheumatoid Arthritis
Osteoarthritis
Autoimmune
Multiple Sclerosis
Immune Disease
Autoimmune Disease
Antibodies
Astaxanthin
Hyaluronate
Hyaluronic Acid
Joint Pain
Hyaluronan
Immune Diseases
Autoimmune Diseases
Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Rheumatoid Arthritis patents



      
           
This page is updated frequently with new Rheumatoid Arthritis-related patents. Subscribe to the Rheumatoid Arthritis RSS feed to automatically get the update: related Rheumatoid RSS feeds.

Subscribe to updates on this page: Rheumatoid Arthritis RSS RSS

Date/App# patent app List of recent Rheumatoid Arthritis-related patents
04/17/14
20140107322
 Methods of use of soluble cd24 for therapy of rheumatoid arthritis patent thumbnailnew patent Methods of use of soluble cd24 for therapy of rheumatoid arthritis
Provided herein is a cd24 protein. The cd24 protein may include mature human or mouse cd24, as well as a n- or c-terminally fused portion of a mammalian immunoglobulin..
04/17/14
20140107097
 Heteroaryl linked quinolinyl modulators of roryt patent thumbnailnew patent Heteroaryl linked quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/17/14
20140107096
 Heteroaryl linked quinolinyl modulators of roryt patent thumbnailnew patent Heteroaryl linked quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/17/14
20140107094
 Methylene linked quinolinyl modulators of roryt patent thumbnailnew patent Methylene linked quinolinyl modulators of roryt
The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating rorγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1..
04/17/14
20140106381
 Method for the diagnosis of rheumatoid arthritis patent thumbnailnew patent Method for the diagnosis of rheumatoid arthritis
The present invention refers to the use of citrullinated synthetic peptides for the diagnosis of rheumatoid arthritis (ra).. .
04/10/14
20140100250
 Pyridyl aminopyridines as syk inhibitors patent thumbnailPyridyl aminopyridines as syk inhibitors
The present invention provides novel pyrimidine amines of formula i which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, copd, rheumatoid arthritis, and cancer.. .
04/10/14
20140099708
 Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders patent thumbnailAnti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
The present invention relates to antibodies that specifically bind to il12rβ1, the non-signal transducing chain of both the heterodimeric il12 and il23 receptors. The invention more specifically relates to specific antibodies that are il12 and il23 receptor antagonists capable of inhibiting il12/il18 induced ifnγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting ifnγ production, il12 and/il23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders..
04/10/14
20140099323
 Methods for treatment of inflammatory diseases patent thumbnailMethods for treatment of inflammatory diseases
It provides methods and pharmaceutical compositions comprising antagonists to the protein bile salt-stimulated lipase (bssl) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising bssl antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis.
03/27/14
20140088415
 Medical imaging devices, methods, and systems patent thumbnailMedical imaging devices, methods, and systems
The disclosed subject matter includes devices, methods, and systems for generating optical tomographic data including volumetric and surface geometric data. The disclosed subject matter also includes devices, methods, and systems for generating optical tomographic data for purposes of diagnosing rheumatoid arthritis..
03/27/14
20140086895
 Methods and pharmaceutical compositions for the treatment of autoimmune diseases patent thumbnailMethods and pharmaceutical compositions for the treatment of autoimmune diseases
The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune diseases, especially rheumatoid arthritis. More particularly, the present invention relates to an a-enolase polypeptide for use in the prophylactic treatment of an autoimmune disease in a subject in need thereof..
03/20/14
20140080879
Factor viia inhibitor
The present invention relates to novel inhibitors of factors viia, ixa, xa, xia, in particular factor viia, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed..
03/20/14
20140079719
Il-17 antagonistic antibodies
An il-17 binding molecule, in particular an antibody to human il-17, more preferably a human antibody to human il-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an il-17 mediated disease or disorder, e.g. Rheumatoid arthritis..
03/20/14
20140079708
Antibody molecule for human gm-csf receptor alpha
Binding members for alpha chain of receptor for granulocyte macrophage colony stimulating factor (gm-csfrα), especially antibody molecules. Use of the binding members in treating inflammatory and autoimmune diseases, e.g.
03/20/14
20140079699
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis..
03/13/14
20140073572
Targeting complement factor h for treatment of diseases
The invention provides a cr2-fh molecule comprising a cr2 portion comprising cr2 protein or a fragment thereof and a fh portion comprising a factor h protein or a fragment thereof, and pharmaceutical compositions comprising a cr2-fh molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion..
03/13/14
20140072576
Chemokine receptor antagonists and use thereof
Wherein all symbols are as defined here, a salt thereof, a solvate thereof, or a prodrug thereof. The compound of the present invention has an antagonistic activity against cxcr4 and is therefore useful as a preventive and/or therapeutic agent for cxcr4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, retinopathy, pulmonary fibrosis, rejection of transplanted organ, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiovascular disease, metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), or an agent for regeneration therapy..
03/13/14
20140072573
Method of treating rheumatoid arthritis
Treating the patient until a basal level of soluble ve-cadherin is reached.. .
03/13/14
20140072551
Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
The invention features antibodies, e.g., chimeric and humanized antibodies, that recognize (i.e., bind) p-selectin. The p-selectin antibodies prevent p-selectin from binding to its cognate receptor.
03/06/14
20140066520
Novel anti-inflammatory cyclooxygenase inhibitors
Disclosed is a pharmaceutical composition including a therapeutic quantity of a cox-2 inhibitor having an ic50-whma cox-2/cox-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition..
02/27/14
20140057877
Therapeutic polyamine compositions and their synthesis
This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and ppar partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicity of neurotoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan.
02/27/14
20140056888
High concentration antibody formulations
The present disclosure relates to, inter alia, stable aqueous solutions comprising a high concentration of an antibody that binds to human complement component c5 and methods for preparing the solutions. The disclosure also provides methods for treating or preventing complement-associated disorders (for example, age-related macular degeneration or rheumatoid arthritis) using the solutions.
02/27/14
20140056886
Humanized anti-il-20 antibody and uses thereof
Humanized antibodies specific to human interleukin 20 (il-20) and uses thereof in treating diseases associated with the il-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.. .
02/27/14
20140056885
Subcutaneously administered anti-il-6 receptor antibody
The present application discloses methods for treating an il-6-mediated disorder such as rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia), systemic jia (sjia), polyarticular course jia (pcjia), systemic sclerosis, or giant cell arteritis (gca), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-il-6r antibody). In particular, it relates to identification of a fixed dose of anti-il-6r antibody, e.g.
02/27/14
20140056884
Subcutaneously administered anti-il-6 receptor antibody
The present application discloses methods for treating an il-6-mediated disorder such as rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia), systemic jia (sjia), polyarticular course jia (pcjia), systemic sclerosis, or giant cell arteritis (gca), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-il-6r antibody). In particular, it relates to identification of a fixed dose of anti-il-6r antibody, e.g.
02/27/14
20140056883
Subcutaneously administered anti-il-6 receptor antibody
The present application discloses methods for treating an il-6-mediated disorder such as rheumatoid arthritis (ra), juvenile idiopathic arthritis (jia), systemic jia (sjia), polyarticular course jia (pcjia), systemic sclerosis, or giant cell arteritis (gca), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-il-6r antibody). In particular, it relates to identification of a fixed dose of anti-il-6r antibody, e.g.
02/27/14
20140056809
Treatment and diagnosis of macrophage mediated disease
Where the group ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group x comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, x comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis..
02/20/14
20140051655
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
Alpha 4 inhibitors are used in treatment of inflammatory and autoimmune diseases, such as multiple sclerosis, crohn's disease, rheumatoid arthritis and asthma. Rare occurrences of progressive multifocal leucoencephalopathy during treatment with an alpha-4 agent suggest the possibility that it may be related to such treatment.
02/20/14
20140050696
Novel bisaminoquinoline compounds, pharmaceutical compositions prepared therefrom and their use
The present invention relates to novel bisaminoquinoline compounds, pharmaceutical compositions comprising these novel compounds and methods for inhibiting autophagy in biological systems. Methods of treating cancer in patients in need using compounds and/or compositions according to the present invention alone or in combination with at least one additional anticancer agent represent additional aspects of the invention.
02/13/14
20140045840
Compounds and methods for kinase modulation, and indications therefor
Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, or forms thereof are active on fms protein kinase, or on fms and kit protein kinase, or on fms and flt-3 protein kinase.
02/06/14
20140038987
Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of formula (ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the s1p1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, microbial infections or diseases and viral infections or diseases..
02/06/14
20140038944
Furo[3, 2-b] pyrr0l-3-ones as cathespin s inhibitors
Compounds of formula (i) exhibit surprisingly high efficacies for human cathepsin s, excellent selectivity verses other mammalian cathepsins and are useful for treatment of diseases such as rheumatoid arthritis, multiple sclerosis, myasthenia gravis, transplant rejection, diabetes, sjogrens syndrome, grave's disease, systemic lupus erythematosis, osteoarthritis, psoriasis, idiopathic thrombocytopenic purpura, allergic rhinitis, asthma, atherosclerosis, obesity, chronic obstructive pulmonary disease and chronic pain.. .
02/06/14
20140037725
Bilayer pharmaceutical compositions of naproxen
The present invention is related to a bilayer pharmaceutical composition comprising naproxen or a pharmaceutically acceptable salt thereof. The present invention is particularly related to a bilayer pharmaceutical composition comprising an immediate release component and a controlled release component of naproxen or a pharmaceutically acceptable salt thereof and the process for preparation thereof.
02/06/14
20140037646
Mmp8 inactivating antigen binding proteins
Described are mmp8 inactivating antigen binding proteins, such as antigen binding proteins comprising an amino acid sequence that comprises 4 framework regions and 3 complementary determining regions; further described is the use of such antigen binding proteins to treat inflammation, such as, but not limited to, systemic inflammatory response syndrome, sepsis, lps induced inflammation, renal ischemia/reperfusion injury, ventilation induced lung injury, periodontal inflammation, rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, lyme arthritis and osteoarthritis.. .
02/06/14
20140037549
Genetic markers for prognosis of rheumatoid arthritis treatment efficacy
The present invention discloses markers useful in predicting the responsiveness of a subject having, or at risk of developing rheumatoid arthritis (ra) to treatment with anti-tnf agents. Particularly, the present invention discloses the allelic configuration of the cd6 gene and/or the stxbp6 gene which is indicative of the degree of responsiveness to anti-tnfα treatment of ra..
01/30/14
20140031563
New compounds for inhibiting differentiation of osteoclast and pharmaceutical composition comprising thereof
New compounds and pharmaceutical compositions comprising active ingredients having inhibition effects on osteoclast differentiation are provided. The pharmaceutical compositions comprising the new compounds can be used as medicines for treating metabolic bone diseases such as bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone, and paget's disease..
01/30/14
20140031355
Heterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on or associated with pi 105 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer..
01/23/14
20140024056
Surrogates of post-translationally modified proteins and uses thereof
The present invention provides compounds that are surrogates of post-translationally modified proteins and uses thereof. Numerous diseases are associated with post-translationally modified proteins that are difficult to obtain in homogenous form and in quantities needed for immunization and use as convenient standards, calibrators, and/or reference compounds that facilitate the detection and analysis of endogenous post-translationally modified proteins.
01/23/14
20140023634
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
01/23/14
20140023614
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
The present invention relates to substituted fused tricyclic compounds of formula (i) or (ia), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by jak activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by jak activity.
01/16/14
20140017273
Albumin-fused anti-angiogenesis peptides
The present disclosure relates to albumin fusion protein including an angiogenesis inhibiting peptide, or a fragment or variant thereof, and albumin, or a fragment or variant thereof. The fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution.
01/16/14
20140017235
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain..
01/09/14
20140011888
Composition derived from astaxanthin and method to treat joint pain associated with osteoarthritis
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
01/09/14
20140011755
Cardiac glycosides for treating autoimmune disease
The invention provides methods for treating inflammatory and autoimmune diseases by administering to the subject an effective amount of a cardiac glycoside, where the dose is effective to suppress or prevent initiation, progression, or relapses of the disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject determined to have rheumatoid arthritis or systemic lupus, or a pre-clinical disease state thereof, an effective amount of a cardiac glycoside, to suppress or prevent activity of the disease.
01/02/14
20140005267
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
01/02/14
20140005176
2-phenoxy- and 2-phenylsulfonamide derivatives with ccr3 antagonistic activity for the treatment of inflammatory or immunological disorders
Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with ccr3 antagonistic activity. These compounds are useful for the treatment of diseases associated with ccr3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, grave's disease, hiv infection, alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders..
01/02/14
20140004106
Stable igg4 based binding agent formulations
The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an igg4 binding agent and a citrate buffer, wherein the ph of the formulation is at or below both ph 6 and the pi of the binding agent. The formulations can be used in the treatment of chronic bowel diseases or rheumatoid arthritis..
12/26/13
20130345277
Modulators of gtpase and use in relevant treatment
The present invention relates to molecules which function as selective modulators of the ras-homologous (rho) family of small gtpases, in particular, cdc42 gtpase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of cdc42 gtpase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type i, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including chlamydia infections, e. Coli infections, h.
12/26/13
20130345194
Substituted cyclopentyl-azines as casr-active compounds
The invention relates to compounds of general formula (i), wherein r1, r2, r3, r4, r5, m, n are defined herein, and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, as jak kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, type i diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, crohn's disesase, alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.. .
12/26/13
20130345183
Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine
A method of treating rheumatoid arthritis using a water-soluble cocrystal composition contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer selected from an alpha variant of theanine or a beta variant of theanine or other form of theanine.. .
12/26/13
20130345163
Biological marker for inflammation
Inflammatory state in a subject is assayed by determining the level of expression of a3 adenosine receptor (a3ar) in white blood cells (wbc), e.g. Circulating wbcs, from the subject.
12/26/13
20130345086
Cd4+ t-cell gene signature for rheumatoid arthritis (ra)
The present invention relates to methods and products for the identification and diagnosis of rheumatoid arthritis (ra), in particular for the diagnosis of anti-citrullinated peptide antibody (acpa)-negative ra. Most particularly the invention relates to a gene expression signature comprising at least 12 biomarkers for use in the prognosis or diagnosis of ra..
12/26/13
20130344037
Treatment of inflammatory diseases using placental stem cells
Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (alibert-bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.. .
12/19/13
20130338496
Medical imaging devices, methods, and systems
Devices, methods, and systems for providing optical imaging to detect and characterize anatomical and/or physiological indicators, such as, rheumatoid arthritis, and devices, methods and systems for computer aided detection and diagnosis of tomographic images. Embodiments for optimizing machine classification of tissue samples are described.
12/19/13
20130338164
Multimeric vla-4 antagonists comprising polymers moieties
Disclosed are conjugates which bind vla-4. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by vla-4.
12/19/13
20130338160
Compounds with (1e, 6e)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; kennedy's disease (spinal and bulbar muscular atrophy, or sbma), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein.
12/12/13
20130331310
Prodrug of an ice inhibitor
Compound i is useful for treating il-1 mediated diseases such as rheumatoid arthritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, inflammatory peritonitis, septic shock, pancreatitis, traumatic brain injury, organ transplant rejection, osteoarthritis, asthma, psoriasis, alzheimer's disease, myocardial infarction, congestive heart failure, huntington's disease, atherosclerosis, atopic dermatitis, leukemias and related disorders, myelodysplastic syndrome, uveitis or multiple myeloma.. .
12/12/13
20130330402
Antinuclear antibody utilized as a targeting agent for pharmaceutical compounds used in the treatment of cancer and other diseases
This invention describes a method whereby autoimmune antinuclear antibodies are used as a targeting agent to deliver drug nanoparticles or drug liposomes to the tumor or disease site. The antinuclear antibodies have the propensity to localize in areas of tissue necrosis where dead cells have released their nuclear material into the extracellular environment.
12/05/13
20130324698
Anti-syndecan-4 antibodies
The present invention relates to a recognition molecule against syndecan-4, wherein said recognition molecule binds an epitope contained in an amino acid sequence corresponding to the amino acid sequence between amino acids 93 and 121 of the amino acid sequence shown in seq id no: 1 (fig. 1) for use in the treatment and/or prevention of a pathological medical condition associated with turnover of the extracellular matrix and/or cartilage remodelling in which syndecan-4 is involved.
12/05/13
20130324504
Antispasmodic 1,2-diols and 1,2,3-triols
The present invention is directed to pharmaceutical compositions comprising antispasmodic c4-c8aliphatic-1,2-diols and c4-c8aliphatic-1,2,3-triols and their use to relieve the spasms associated with pain. These agents may be administered topically or orally and may be combined with anti-inflammatory agents such as a non-steroidal anti-inflammatory drug or a corticosteroid.
12/05/13
20130323746
Genotoxicity as a biomarker for inflammation
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation.
12/05/13
20130323240
Humanized antibodies against light and uses thereof
The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the light polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g.
11/28/13
20130317027
Compounds and therapeutic uses thereof
The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, t-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.. .
11/28/13
20130315894
Genetic polymorphisms associated with rheumatoid arthritis, metods of detection and uses thereof
The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection..
11/28/13
20130315893
Humanized anti-il-20 antibody and uses thereof
The present disclosure provides humanized antibodies specific to human interleukin 20 (il-20) and uses thereof in treating diseases associated with the il-20 signaling pathway, e.g., osteoporosis, inflammatory disease (e.g., rheumatoid arthritis), cancer, stroke, and renal failure.. .
11/28/13
20130315880
Abcb5 positive mesenchymal stem cells as immunomodulators
The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the abcb5 p-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used.
11/21/13
20130310337
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha
Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated epa and dha either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.. .
11/21/13
20130310272
Method for evaluating the presence of rheumatoid arthritis and biomarker set used in the same
An object is to provide a method for evaluating presence of rheumatoid arthritis by using a new biomarker set. The object is achieved by a method for evaluating presence of rheumatoid arthritis, in which the method includes the steps of: acquiring, from a biological specimen obtained from a subject, information regarding expression level of a first biomarker which is slc16a4, and information regarding expression level of at least one second biomarker selected from the group consisting of slco2b1, ptprm, shb, and atp9a; and evaluating presence of rheumatoid arthritis in the subject based on the information regarding expression levels of the acquired first and second biomarkers..
11/21/13
20130309241
Methods of treating vascular disease using il-1beta antagonists
This invention relates to a novel use of il-1□-ligand/il-1 receptor disrupting compounds (herein referred to as “il-1beta compounds”); such as small molecular compounds disrupting il-1□ ligand—il-1 receptor interaction, il-1□ antibodies or il-1 receptor antibodies, e.g. Il-1□ binding molecules described herein, e.g.
11/21/13
20130309239
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
The invention relates to antibodies that are capable of specifically binding trem-1 and preventing the activation of trem-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease..
11/21/13
20130309229
Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
Methods are disclosed for treating or inhibiting an autoimmune disease in a subject. In some embodiments, the disclosed methods include administering to the subject a therapeutically effective amount of one or more major histocompatibility complex (mhc) molecules including covalently linked first, second and third domains; wherein the first domain is an mhc class ii β1 domain and the second domain is an mhc class ii α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain; or wherein the first domain is an mhc class i α1 domain and the second domain is an mhc class i α2 domain, wherein the amino terminus of the α2 domain is covalently linked to the carboxy terminus of the α1 domain; and wherein the third domain is covalently linked to the first domain and comprises an antigen associated with the autoimmune disorder.


Popular terms: [SEARCH]

Rheumatoid Arthritis topics: Rheumatoid Arthritis, Osteoarthritis, Autoimmune, Multiple Sclerosis, Immune Disease, Autoimmune Disease, Antibodies, Astaxanthin, Hyaluronate, Hyaluronic Acid, Joint Pain, Hyaluronan, Immune Diseases, Autoimmune Diseases, Lung Cancer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patents related to Rheumatoid Arthritis for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Rheumatoid Arthritis with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3353

3982

0 - 1 - 71